Subject : Evaluation of treatment approaches for suspected underactive bladder (UAB): Clinical preference and patient outcomes
Underactive bladder (UAB) or detrusor underactivity (DU) is a challenging condition that affects 45% of men and women over 70 years of age. Its management revolves around the primary objective to relieve voiding difficulty, reduce postvoid residual urine, and urinary tract infection. Clean intermittent catheterization (CIC) is the standard of care and the recommended treatment option; however, CIC has its own limitations that include urethral strictures, urethral false passages, hematuria, bacteriuria, and labial erosion. Pharmacological management of UAB is aimed at increasing intravesical pressure and detrusor contractility while decreasing bladder outlet resistance. Bethanechol is a cholinergic agonist that induces contraction of the detrusor muscle. It has demonstrated efficacy in a selected group of patients. Recent study (Gaitonde S, et al. 2019) has demonstrated that bethanechol was prescribed in patients with atony of bladder, urinary retention, neurogenic bladder, urinary incontinence, and incomplete bladder emptying.
The objective of this survey is to evaluate current practice of Urologists, their perception and position of Bethanechol in management of underactive bladder.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of (INR {{$contractAmount}}), on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})